Cost-Effectiveness Analysis of Leuprorelin Acetate Atrigelin the Treatment of Prostate Cancer

Abstract

This study aimed to evaluate the clinical effectiveness and cost of leuprorelin acetate Atrigel (Eligard®) in prostate cancer treatment and calculate its cost-effectiveness compared with other luteinizing hormonereleasing hormone (LHRH) agonists (leuprolide acetate microsphere [Lucrin®], goserelin [Zoladex LA®], and triptorelin [Decapeptyl®]).METHODSThe primary health-related outcome was life-years gained, and effectiveness was measured through the difference between treatment options. Analyses were performed separately for testosterone suppression targets of